Eli Lilly and Company (NYSE:LLY) Stock Has Consensus Target Price of $1,404.14

Shares of Eli Lilly and Company (NYSE:LLY) have been given a consensus rating of “Moderate Buy” by the twenty-nine ratings firms that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, three have given a hold rating, twenty-four have issued a buy rating and one has given a strong buy rating to the company. The average 12 month target price among analysts that have covered the stock in the last year is $1,416.64.

A number of research firms recently commented on LLY. Cantor Fitzgerald boosted their price objective on shares of Eli Lilly and Company from $1,440.00 to $1,600.00 and gave the stock an “overweight” rating in a report on Monday, November 2nd. UBS Group increased their target price on shares of Eli Lilly and Company from $1,425.00 to $1,625.00 and gave the company a “buy” rating in a report on Friday, October 30th. Leerink Partners lifted their price target on shares of Eli Lilly and Company from $1,309.00 to $1,316.00 and gave the company an “outperform” rating in a research report on Wednesday, October 21st. Truist Financial reissued a “buy” rating and set a $1,612.00 price target (up from $1,376.00) on shares of Eli Lilly and Company in a research note on Friday, October 30th. Finally, Berenberg Bank raised Eli Lilly and Company from a “hold” rating to a “buy” rating and set a $1,400.00 price target on the stock in a research note on Tuesday, September 15th.

Key Headlines Impacting Eli Lilly and Company

These are some of the LLY headlines that stood out recently:

• Positive Sentiment: Lilly reported positive 52-week Phase 3b results for Taltz plus Zepbound in adults with psoriatic arthritis and obesity. Nearly three times as many combination-treatment patients achieved at least a 50% reduction in disease activity versus Taltz alone, potentially broadening Zepbound’s use and commercial opportunity. Article: Phase 3b Taltz and Zepbound results
• Positive Sentiment: Foundayo, Lilly’s GLP-1 weight-loss pill, was reported to have shown substantial improvement in sleep apnea, adding to the potential uses of the company’s obesity pipeline. Article: Foundayo and sleep apnea
• Positive Sentiment: A recent report says Lilly raised its 2026 sales outlook to as much as $92 billion, reinforcing expectations that strong demand for its obesity and diabetes medicines can drive continued growth. Article: Lilly’s 2026 sales outlook

Eli Lilly and Company Price Performance

Shares of NYSE LLY opened at $1,437.46 on Friday. The firm has a market capitalization of $1.35 trillion, a P/E ratio of 46.66, a PEG ratio of 1.72 and a beta of 0.40. Eli Lilly and Company has a one year low of $850.51 and a one year high of $1,453.00. The company’s fifty day moving average is $1,231.13 and its two-hundred day moving average is $1,106.42. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.00 and a current ratio of 1.39.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings results on Thursday, October 29th. The company reported $7.48 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.71 by $1.77. The business had revenue of $24.40 billion during the quarter, compared to the consensus estimate of $22.58 billion. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. The business’s revenue was up 38.6% compared to the same quarter last year. During the same quarter last year, the firm posted $7.02 EPS. Analysts forecast that Eli Lilly and Company will post 35.67 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, December 10th. Investors of record on Friday, November 13th will be issued a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, November 13th. This represents a $6.92 annualized dividend and a yield of 0.5%. Eli Lilly and Company’s payout ratio is currently 22.46%.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, EVP Anat Hakim sold 5,000 shares of the company’s stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $1,402.52, for a total value of $7,012,600.00. Following the sale, the executive vice president owned 4,137 shares of the company’s stock, valued at approximately $5,802,225.24. This represents a 54.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the firm’s stock in a transaction on Monday, August 17th. The shares were sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the completion of the transaction, the executive vice president owned 54,147 shares of the company’s stock, valued at approximately $63,628,139.70. This represents a 10.72% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.14% of the company’s stock.

Institutional Investors Weigh In On Eli Lilly and Company

Several institutional investors and hedge funds have recently made changes to their positions in LLY. Red Oak Financial Group LLC grew its holdings in Eli Lilly and Company by 24.8% during the 3rd quarter. Red Oak Financial Group LLC now owns 694 shares of the company’s stock valued at $803,000 after buying an additional 138 shares during the last quarter. Mayflower Financial Advisors LLC increased its position in Eli Lilly and Company by 2.5% during the third quarter. Mayflower Financial Advisors LLC now owns 4,004 shares of the company’s stock worth $4,633,000 after buying an additional 98 shares in the last quarter. Advisors Asset Management Inc. purchased a new position in Eli Lilly and Company during the third quarter worth $81,217,000. Edmond DE Rothschild Holding S.A. raised its holdings in shares of Eli Lilly and Company by 7.2% in the third quarter. Edmond DE Rothschild Holding S.A. now owns 56,713 shares of the company’s stock worth $65,621,000 after acquiring an additional 3,829 shares during the last quarter. Finally, GW&K Investment Management LLC raised its holdings in shares of Eli Lilly and Company by 2.9% in the third quarter. GW&K Investment Management LLC now owns 21,476 shares of the company’s stock worth $24,849,000 after acquiring an additional 610 shares during the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Company Profile

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management. The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.